August 6th 2025
Dordaviprone (Modeyso) is now approved to treat recurrent H3 K27M-mutant diffuse midline glioma, an ultra-rare, aggressive brain tumor primarily affecting children.
The Economics of Transthyretin-Mediated Amyloidosis: Balancing Equity and Access in Resource Allocation
Advancing Immunotherapy in Endometrial Cancer: A Managed Care Perspective on Personalized Care
Dr Kerin Adelson on Changes in Care Coordination Precipitated by OCM
Cancer Does Not Stop for COVID-19, but Reform Becomes a Challenge
Counties Experiencing Persistent Poverty Have Higher Cancer Mortality Rates
Dr Kashyap Patel Discusses COVID-19 Implications for PCOC® 2020